Liquid biopsies are non-invasive tests that analyze circulating tumor cells (CTCs) and cell-free DNA (cfDNA) fragments found in the bloodstream. These tests can provide insights into the presence, type, and progression of cancer without requiring a traditional tissue biopsy.
Traditional tissue biopsies are invasive, painful, and sometimes difficult to obtain. Liquid biopsies offer a non-invasive alternative that can be performed repeatedly over time, providing continuous monitoring of the patient's condition without additional invasiveness.
Advanced sequencing technologies, such as next-generation sequencing (NGS), are employed to identify specific genetic markers or mutations present in CTCs and cfDNA. By analyzing these genetic signatures, clinicians can detect the presence of cancer, monitor disease progression, and even predict treatment response.
The manufacturing process involves developing and validating assays for CTC capture and cfDNA extraction from blood samples. This includes optimizing cell isolation techniques, ensuring accurate sequencing, and creating robust bioinformatics pipelines to interpret results.
The build process typically starts with the development of specialized microfluidic devices or magnetic beads for capturing CTCs. These are then integrated into a larger system that processes multiple samples simultaneously. The cfDNA is extracted using enzymatic digestion followed by purification steps, and both CTCs and cfDNA are sequenced using NGS platforms.
Curated names only — none are invented. Use the link to find more.
Cost drivers only — no verified dollar figures are shown. Check live sources for prices.
Illustrative — search real, dated examples rather than trusting a generated story.
Live searches — we don't list papers we can't verify.
Live patent searches — filings are never listed from memory.
Verify against primary sources only.
Source: curated technology intelligence stream with tracked references.